| First Author | Wu N | Year | 2016 |
| Journal | Oncotarget | Volume | 7 |
| Issue | 36 | Pages | 57514-57524 |
| PubMed ID | 27613844 | Mgi Jnum | J:320544 |
| Mgi Id | MGI:6873354 | Doi | 10.18632/oncotarget.11583 |
| Citation | Wu N, et al. (2016) NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer. Oncotarget 7(36):57514-57524 |
| abstractText | Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor type that is typically metastatic upon diagnosis. We have a poor understanding of the factors that control SCLC progression and metastasis. TheNFIB transcription factor is frequently amplified in mouse models of SCLC, but clear evidence that NFIB promotes SCLC in vivo is lacking. We report that in mouse models, Nfib amplifications are far more frequent in liver metastases over primary SCLC, suggesting roles in tumor progression/metastasis. Overexpression of Nfib in a sensitized mouse model led to acceleration of SCLC, indicating that Nfib functions as a bona fide oncogene. Suppression of Nfib expression in cell lines derived from the doxycycline-inducible Rb/p53/TET-Nfib model led to increased apoptosis and suppression of proliferation. Transcriptional analysis revealed that Nfib regulates the expression of genes related to axon guidance, focal adhesion and extracellular matrix-receptor interactions. These data indicate that Nfib is a potent oncogene in SCLC, and the enrichment of Nfib amplifications in liver metastases over primary SCLC points to Nfib as a candidate driver of SCLC metastasis. |
